Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15468170 | 1.00 | HSD17B10 (0.52) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5517050 | 1.00 | HSD17B10 (0.52) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL21547377 | 1.00 | HSD17B10 (0.52) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL12344760 | 1.00 | HSD17B10 (0.52) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL16645332 | 1.00 | HSD17B10 (0.52) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| Bromide SCHEMBL2542868 | 0.98 | HSD17B10 (0.50) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1375642 | 0.98 | HSD17B10 (0.50) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL16645317 | 0.93 | HSD17B10 (0.47) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL29299530 | 0.91 | HSD17B10 (0.45) | HSD17B10MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL20686921 | 0.91 | HSD17B10 (0.45) | HSD17B10MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271195-B2 | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2007-09-18 | — | — | US | claimed |
| EP-1635800-A2 | CARBONYL COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| US-20050026907-A1 | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2005-02-03 | — | — | US | claimed |
| WO-2004110418-A2 | CARBONYL COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2004-12-23 | — | — | WO | claimed |
| CN-118084892-A | Compounds useful as HPK1 inhibitors | 深圳福沃药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-3954679-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-11-02 | — | — | US | disclosed |
| EP-3409667-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-11034718-B2 | C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2021-06-15 | — | — | US | disclosed |
| US-11034718-B2 | C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2021-06-15 | — | — | US | disclosed |
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2021-01-14 | — | — | US | disclosed |
| WO-2020154683-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20060030554-A1 | Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. | 2006-02-09 | — | — | US | disclosed |
| WO-2005123089-A2 | MULTICYCLIC SULFONAMIDE COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005120515-A2 | NOVEL SULFONAMIDES AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| US-20050026907-A1 | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2004110418-A2 | CARBONYL COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| US-5532255-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034718-B2 | C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors | IL17A, CDK17, CCR3 | HSD17B10 90/4885MEN1 4501/4885KMT2A 3663/4885 |
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | HSD17B10 4616/4885MEN1 786/4885KMT2A 1384/4885 |
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | HSD17B10 967/4885MEN1 2845/4885KMT2A 4689/4885 |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | OPRL1, MGLL, VKORC1L1 | HSD17B10 670/4885MEN1 1235/4885KMT2A 4106/4885 |
| US-20050026907-A1 | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease | HDAC6, HDAC5, HDAC1 | HSD17B10 626/4885MEN1 4045/4885KMT2A 64/4885 |
| US-20060030554-A1 | Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease | HDAC6, HDAC3, HDAC5 | HSD17B10 812/4885MEN1 4446/4885KMT2A 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.